home / stock / annx / annx news

ANNX News and Press, Annexon Inc. From 06/04/24

Stock Information
Company Name: Annexon Inc.
Stock Symbol: ANNX
Market: NASDAQ
Website: annexonbio.com
Menu
ANNX ANNX Quote ANNX Short ANNX News ANNX Articles ANNX Message Board
Get ANNX Alerts

News, Short Squeeze, Breakout and More Instantly...
ANNX - Annexon: Complement Inhibition Of GBS Only The Beginning With Strong Tech In Place

2024-06-04 14:07:57 ET Summary Annexon, Inc. primary endpoint met with statistical significance in phase 3 Bangladesh and Philippines study, using ANX005 for the treatment of patients with Guillain-Barré syndrome. Results from RWS IGOS phase 3 study, using ANX005 for the trea...
ANNX - Annexon Inc. (NASDAQ: ANNX) is One of Tuesday Morning's Most Active Stocks

Annexon, Inc. (NASDAQ: ANNX) is one today's most active stocks by volume. So far today, approximately 36.48M shares of Annexon, Inc. have been exchanged, as compared to an average 30-day volume of 1.44M shares. Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops t...

ANNX - US Companies Moving the Markets, Morning edition
Tue, Jun 04, 2024 as of 10.00 am ET

A look at the top 10 most actives in the United States SOBR Safe Inc. (SOBR) rose 115.1% to $0.5667 on volume of 77,631,052 shares MicroAlgo Inc. (MLGO) rose 284.0% to $5.99 on volume of 40,752,997 shares Crown Electrokinetics Corp. (CRKN) fell 13.8% to $0.1016 on volume of 28,247,104 sha...

ANNX - Annexon spikes as lead asset hits main goal in late-stage study

2024-06-04 07:35:40 ET More on Annexon Biosciences Annexon: Unforced Error Sullies Prospects Biggest stock movers today: GME, HQY, and more Seeking Alpha’s Quant Rating on Annexon Biosciences Historical earnings data for Annexon Biosciences Fin...
ANNX - Annexon Announces Positive Topline Results from Pivotal Phase 3 Trial for First-in-Class C1q Blocking Antibody ANX005 in Guillain-Barré Syndrome

Single Infusion of ANX005 30 mg/kg Met Primary Endpoint, Delivering a Highly Statistically Significant and Clinically Meaningful 2.4-fold Improvement in GBS-DS vs. Placebo at Week 8, p=0.0058 ANX005 Demonstrated Early and Sustained Improvements in Key Secondary Endpoints Including Muscl...

ANNX - Biggest stock movers today: GME, HQY, and more

2024-06-04 05:23:18 ET More on related stocks: HealthEquity, Inc. (HQY) Q1 2025 Earnings Call Transcript BARK, Inc. (BARK) Q4 2024 Earnings Call Transcript GameStop Stock: Disconnected From Fundamentals GameStop shares leap 21%; ‘Roaring Kitty’ ...

ANNX - Annexon Biosciences to Host Conference Call and Webcast to Discuss GBS Phase 3 Data

BRISBANE, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with devastating inflammatory-related diseases, today announced that it will host a conference call a...
ANNX - CRSP, NYMT and SBRA are among after hour movers

2024-05-17 17:05:06 ET Gainers: Stronghold Digital Mining ( SDIG ) +7% . New York Mortgage Trust ( NYMT ) +3% . Outbrain  ( OB ) +3% . Aquestive Therapeutics ( AQST ) +2% . Airship AI Holdings ( AISP ) +2% . Losers: ...

ANNX - Annexon Biosciences GAAP EPS of -$0.21 beats by $0.12

2024-05-13 08:51:29 ET More on Annexon Biosciences Annexon: Unforced Error Sullies Prospects Seeking Alpha’s Quant Rating on Annexon Biosciences Historical earnings data for Annexon Biosciences Financial information for Annexon Biosciences Re...

ANNX - Annexon Reports First Quarter 2024 Financial Results and Key Anticipated Milestones

Multiple Value-creating Catalysts Across the Annexon Portfolio Throughout 2024 Pivotal Phase 3 Data for ANX005 in Guillain-Barré Syndrome (GBS) Expected in Second Quarter 2024; Potential to be the First Targeted Treatment for GBS New Phase 2 Data Showing Neuroprotection of Vi...
Previous 10 Next 10